- Home
- SNTI vs CNVS Comparison
SNTI vs CNVS Comparison
Compare SNTI & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNTI | CNVS |
|---|---|---|
| Founded | 2016 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Video Chains |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 46.9M |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | SNTI | CNVS |
|---|---|---|
| Price | $1.07 | $2.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $9.00 | $9.00 |
| AVG Volume (30 Days) | ★ 4.5M | 128.4K |
| Earning Date | 11-13-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $79,791,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $150.00 | $30.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 77.29 |
| 52 Week Low | $1.06 | $2.03 |
| 52 Week High | $5.10 | $7.39 |
Technical Indicators
Market Signals| Indicator | SNTI | CNVS |
|---|---|---|
| Relative Strength Index (RSI) | 31.30 | 35.77 |
| Support Level | $1.15 | $2.03 |
| Resistance Level | $1.28 | $2.22 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 0.27 | 20.41 |
Price Performance
Historical ComparisonAbout SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
About CNVS Cineverse Corp.
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.